XOMA's (XOMA) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of XOMA (NASDAQ:XOMA - Free Report) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $123.00 target price on the biotechnology company's stock.

Separately, StockNews.com downgraded XOMA from a "hold" rating to a "sell" rating in a report on Friday, December 27th.

XOMA Trading Down 2.3 %

Shares of XOMA stock traded down $0.60 during trading hours on Tuesday, reaching $25.67. 40,063 shares of the company's stock were exchanged, compared to its average volume of 38,341. The firm has a market capitalization of $302.47 million, a price-to-earnings ratio of -7.38 and a beta of 0.92. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 52-week low of $18.57 and a 52-week high of $35.00. The company has a fifty day moving average of $29.28 and a 200-day moving average of $27.95.

Insider Buying and Selling at XOMA

In other news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the transaction, the chief executive officer now owns 34,979 shares of the company's stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 7.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in XOMA. Geode Capital Management LLC raised its position in shares of XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock worth $4,840,000 after purchasing an additional 1,138 shares during the period. State Street Corp raised its holdings in XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock worth $3,783,000 after buying an additional 1,754 shares during the period. Bank of New York Mellon Corp lifted its stake in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock valued at $1,484,000 after buying an additional 1,968 shares in the last quarter. Ellsworth Advisors LLC acquired a new position in shares of XOMA in the third quarter worth about $516,000. Finally, Barclays PLC increased its position in shares of XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock worth $298,000 after acquiring an additional 8,447 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company's stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.